Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while maintaining asthma symptom control.
| Condition(s) | Severe Asthma |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Summary | This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while maintaining asthma symptom control. |
| Who can participate | Inclusion Criteria: 1．Provision of informed consent prior to any study-specific procedures. Written informed consent, and assent when applicable for study participation must be obtained prior to any study related procedures being performed (local regulations are to be followed in determining the assent/consent requirements for children and parent\[s\]/guardian\[s\]) and according to international guidelines and/or applicable local guidelines. Age 2. Patient must be aged 12-80 years old, inclusively, at the time of Visit 1(Week -1 to Week 0) For those patients, who are 17 on the day of Visit 1(Week -1 to Week 0) but will turn 18 after this day, will be considered an adolescent for the purposes of this study. Type of Patient and Disease Characteristics 3. Documented history of physician-diag |
| Ages | 12 Years to 80 Years |
| Sex | All |
| Lead sponsor | AstraZeneca |
| Locations | Beijing, China; Beijing, China; Beijing, China; Beijing, China; Beijing, China; Beijing, China (+70 more sites) |
| Start date | 2026-01-28 |
| NCT ID | NCT07363642 |
| Official listing | https://clinicaltrials.gov/study/NCT07363642 |